Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMPH | VCSH | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Fixed Income |
52-Week High | $30.81 | $80.20 |
52-Week Low | $16.87 | $78.41 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VCSH trades at $78.61, up 0.17% with neutral technical signals. The ETF offers a short 2.7-year duration and a 4.77% yield, attracting income-focused investors amid stable rate expectations. Recent institutional activity shows mixed positioning, with some firms reducing stakes while others increase holdings. Credit spreads remain tight, limiting near-term upside potential but providing downside protection.
Outlook is cautious due to unattractive entry points and tight spreads. The ETF suits conservative portfolios seeking steady income with low volatility, though limited rate cuts in 2026 may cap gains. Risks include credit spread widening and competition from higher-yielding alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
